Simple, rapid, and extractive spectrophotometric methods were developed for the determination of some fluoroquinolones antibiotics: gemifloxacin mesylate (GMF), moxifloxacin hydrochloride (MXF), and enrofloxacin (ENF) in pure forms and pharmaceutical formulations. These methods are based on the formation of ion-pair complexes between the basic drugs and acid dyes, namely, bromocresol green (BCG), bromocresol purple (BCP), bromophenol blue (BPB), bromothymol blue (BTB), and methyl orange (MO) in acidic buffer solutions. The formed complexes were extracted with chloroform and measured at 420, 408, 416, 415, and 422？nm for BCG, BCP, BPB, BTB, and MO, respectively, for GMF; at 410, 415, 416, and 420 nm for BCP, BTB, BPB, and MO, respectively, for MXF; and at 419 and 414 nm for BCG and BTB, respectively, in case of ENF. The analytical parameters and their effects are investigated. Beer’s law was obeyed in the ranges 1.0–30, 1.0–20, and 2.0–24？μg mL？1 for GMF, MXF, and ENF, respectively. The proposed methods have been applied successfully for the analysis of the studied drugs in pure forms and pharmaceutical formulations. Statistical comparison of the results with the reference methods showed excellent agreement and indicated no significant difference in accuracy and precision. 1. Introduction Fluoroquinolones are the second-generation members of quinolone antibiotics fluorinated in position 6 and bearing a piperazinyl moiety at position. They are considered to be the most effective Gram-positive and Gram-negative pathogens to combat infection caused by microorganisms that are resistant to other microbials, such as tetracyclines. Also, they have some activity against mycobacteria, mycoplasmas, rickettsias, and the protozoan Plasmodium falciparum [1–3]. There is a substantial body of literature related to both the mechanism of their action as DNA gyrase inhibitors and the influence of systematic structural modifications on their biological activity. Gemifloxacin mesylate (GMF) is (R,S)-7-[(4Z)-3-(aminomethyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid methanesulfonate. Moxifloxacin (MXF) is {1-cyclopropyl-7-[2,8-diazobicyclo (4.3.0) nonane]-6-fluoro-8-methoxy-1,4 dihydro-4-oxo-3-quinolone carboxylic acid}. Enrofloxacin (ENF) is (1 cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolone carboxylic acid) (Scheme 1). GMF and MXF are fourth-generation synthetic broad-spectrum 8-methoxy fluoroquinolone antibacterial drug derivatives. Due to their clinical advantages, GMF and MXF
References
[1]
S. Budavari, Ed., The Merck Index, Merck and Co., Whitehouse Station, NJ, USA, 13th edition, 2001.
[2]
C. S. Sean, Martindale, The Complete Drug Reference, Royal Pharmaceutical Society, Pharmaceutical Press, London, UK, 36th Edn edition, 2009.
[3]
M. K. Bolon, “The newer fluoroquinolones,” Infectious Disease Clinics of North America, vol. 23, no. 4, pp. 1027–1051, 2009.
[4]
The United States Pharmacopoeia, 35, NF 30, vol. 1, United States Pharmacopeial Convention, Rockville, Md, USA, 2012.
[5]
S. Shamim, N. Sultana, M. S. Arayne, M. Akhtar, and S. Gul, “Optimization and simultaneous determination of gemifloxacin and Non-steroidal anti-inflammatory drugs in bulk, pharmaceutical formulations and human serum by RP-HPLC and its applications,” International Research Journal of Pharmacy and Pharmacology, vol. 2, no. 10, pp. 245–253, 2012.
[6]
B. M. H. Al-Hadiya, A. A. Khady, and G. A. E. Mostafa, “Validated liquid chromatographic-fluorescence method for the quantitation of gemifloxacin in human plasma,” Talanta, vol. 83, no. 1, pp. 110–116, 2010.
[7]
A. S. Amin, H. A. Dessouki, and I. A. Agwa, “Ion-pairing and reversed phase liquid chromatography for the determination of three different quinolones: enrofloxacin, lomefloxacin and ofloxacin,” Arabian Journal of Chemistry, vol. 4, no. 3, pp. 249–257, 2011.
[8]
A. R. Rote and S. P. Pingle, “Reverse phase-HPLC and HPTLC methods for determination of gemifloxacin mesylate in human plasma,” Journal of Chromatography B, vol. 877, no. 29, pp. 3719–3723, 2009.
[9]
N. Sultana, M. S. Arayne, M. Akhtar, S. Shamim, S. Gul, and M. M. Khan, “High-performance liquid chromatography assay for moxifloxacin in bulk, pharmaceutical formulations and serum: application to in-vitro metal interactions,” Journal of the Chinese Chemical Society, vol. 57, no. 4, pp. 708–717, 2010.
[10]
S. I. Cho, J. Shim, M.-S. Kim, Y.-K. Kim, and D. S. Chung, “On-line sample cleanup and chiral separation of gemifloxacin in a urinary solution using chiral crown ether as a chiral selector in microchip electrophoresis,” Journal of Chromatography A, vol. 1055, no. 1-2, pp. 241–245, 2004.
[11]
E. Kim, Y.-M. Koo, and D. S. Chung, “Chiral counter-current chromatography of gemifloxacin guided by capillary electrophoresis using (+)-(18-crown-6)-tetracarboxylic acid as a chiral selector,” Journal of Chromatography A, vol. 1045, no. 1-2, pp. 119–124, 2004.
[12]
A. F. Faria, M. V. N. de Souza, M. V. de Almeida, and M. A. L. de Oliveira, “Simultaneous separation of five fluoroquinolone antibiotics by capillary zone electrophoresis,” Analytica Chimica Acta, vol. 579, no. 2, pp. 185–192, 2006.
[13]
A. Radi, A. Khafagy, A. El-shobaky, and H. El-mezayen, “Anodic Voltammetric determination of gemifloxacin using screen-printed carbon electrode,” Journal of Pharmaceutical Analysis, vol. 3, no. 2, pp. 132–136, 2013.
[14]
A. A. Ensaifi, T. Khayamian, and M. Taei, “Determination of ultra trace amount of enrofloxacin by adsorptive cathodic stripping voltammetry using copper(II) as an intermediate,” Talanta, vol. 78, no. 3, pp. 942–948, 2009.
[15]
A.-E. Radi, T. Wahdan, Z. Anwar, and H. Mostafa, “Electrochemical determination of gatifloxacin, moxifloxacin and sparfloxacin fluoroquinolonic antibiotics on glassy carbon electrode in pharmaceutical formulations,” Drug Testing and Analysis, vol. 2, no. 8, pp. 397–400, 2010.
[16]
S. M. Al-Ghannam, “Atomic absorption spectroscopic, conductometric and colorimetric methods for determination of some fluoroquinolone antibacterials using ammonium reineckate,” Spectrochimica Acta A, vol. 69, no. 4, pp. 1188–1194, 2008.
[17]
H. Salem, “Spectrofluorimetric, atomic absorption spectrometric and spectrophotometric determination of some fluoroquinolones,” American Journal of Applied Sciences, vol. 2, no. 3, pp. 719–729, 2005.
[18]
S. E. K. Tekkeli and A. ？nal, “Spectrofluorimetric methods for the determination of gemifloxacin in tablets and spiked plasma samples,” Journal of Fluorescence, vol. 21, no. 3, pp. 1001–1007, 2011.
[19]
J. Shah, M. R. Jan, I. Inayatullah, and M. N. Khan, “Micellar-enhanced spectrofluorometric quantification of moxifloxacin in pharmaceutical formulations, human urine and plasma samples,” African Journal of Pharmacy and Pharmacology, vol. 5, no. 5, pp. 616–624, 2011.
[20]
M. Kamruzzaman, A.-M. Alam, S. H. Lee et al., “Method for determination of fluoroquinolones based on the plasmonic interaction between their fluorescent terbium complexes and silver nanoparticles,” Microchimica Acta, vol. 174, no. 3, pp. 353–360, 2011.
[21]
S. T. Ulu, “Rapid and sensitive spectrofluorimetric determination of enrofloxacin, levofloxacin and ofloxacin with 2,3,5,6-tetrachloro-p-benzoquinone,” Spectrochimica Acta A, vol. 72, no. 5, pp. 1038–1042, 2009.
[22]
S. S. Panda, B. V. V. R. Kumar, K. S. Rao, V. R. Kumar, and D. Patanaik, “Difference spectrophotometric determination of gemifloxacin mesylate in tablet formulation,” Asian Journal of Biochemical and Pharmaceutical Research, vol. 1, no. 3, pp. 442–447, 2011.
[23]
K. Hajera, “Development and validation of a dissolution test with spectrophotometric analysis for gemifloxacin in tablet dosage form,” International Journal of Research in Pharmaceutical and Biomedical Sciences, vol. 3, no. 1, pp. 90–95, 2012.
[24]
S. Dey, Y. V. Reddy, B. Krishna et al., “Spectrophotometric estimation of gemifloxacin in bulk and pharmaceutical dosage form by UV spectrophotometry,” International Journal of Chemical and Analytical Science, vol. 1, no. 6, pp. 130–133, 2010.
[25]
V. Balaji, S. Poongothai, B. Madhavi et al., “Development and validation of a dissolution test with spectrophotometric analysis for gemifloxacin in tablet dosage form,” Pharma Science Monitor, vol. 2, no. 2, pp. 132–145, 2010.
[26]
M. V. Krishna and D. G. Sankar, “Utility of σ and π-acceptors for the spectrophotometric determination of gemifloxacin mesylate in pharmaceutical formulations,” E-Journal of Chemistry, vol. 5, no. 3, pp. 493–498, 2008.
[27]
M. V. Krishna and D. G. Sankar, “Spectrophotometric determination of gemifloxacin mesylate in pharmaceutical formulations through ion-pair complex formation,” E-Journal of Chemistry, vol. 5, no. 3, pp. 515–520, 2008.
[28]
S. Ganapathy, G. V. H. Raju, D. G. Sankar, and P. Y. Naidu, “Spectrophotometric determination of gemifloxacin in bulk and pharmaceutical formulation,” Asian Journal of Chemistry, vol. 21, no. 8, pp. 6508–6512, 2009.
[29]
Z. Y. Al Shoaibi and A. A. Gouda, “Spectrophotometric methods for the determination of gemifloxacin mesylate in pure form and pharmaceutical formulations,” Analytical Chemistry, vol. 9, no. 1, pp. 1–8, 2010.
[30]
D. Madhuri, K. B. Chandrasekhar, N. Devanna, and G. Somasekhar, “Direct and derivative spectrophotometric determination of gemifloxacin mesylate in pure form and pharmaceutical preparations using π acceptors,” International Journal of Pharma Sciences and Research, vol. 1, no. 4, pp. 222–231, 2010.
[31]
D. Madhuri, K. B. Chandrasekhar, N. Devanna, and G. Somasekhar, “Direct and derivative spectrophotometric estimation of gemifloxacin by chelation with palladium(II) ion,” Rasayan Journal of Chemistry, vol. 3, no. 1, pp. 159–165, 2010.
[32]
D. Jyothirmayee, G. S. Sai Babu, and G. D. Rao, “Spectrophotometric determination of gemifloxacin in pharmaceutical formulations,” Asian Journal of Chemistry, vol. 22, no. 2, pp. 1634–1636, 2010.
[33]
D. M. Dhumal, A. A. Shirkhedkar, and S. J. Surana, “Quantitative determination of moxifloxacin hydrochloride in bulk and ophthalmic solution by UV-spectrophotometry and first order derivative using area under curve,” Der Pharmacia Lettre, vol. 3, no. 3, pp. 453–456, 2011.
[34]
M. Misra, A. K. Misra, P. Zope, G. M. Panpalia, and A. K. Dorle, “Simple and validated UV-spectroscopic method for estimation of moxifloxacin.HCL in bulk and formulation,” Journal of Global Pharma Technology, vol. 2, no. 6, pp. 21–27, 2010.
[35]
P. U. Patel, B. N. Suhagia, and M. M. Patel, “Spectrophotometric methods for estimation of moxifloxacin in pharmaceutical formulations,” Indian Drugs, vol. 42, no. 10, pp. 654–657, 2005.
[36]
A. Ciri？, R. Jeli？, L. Joksovi？, M. Jeliki？-Stankov, and P. Djurdjevi？, “Determination of moxifloxacin in human plasma by derivative UV spectrophotometry in a micellar medium,” Canadian Journal of Analytical Sciences and Spectroscopy, vol. 52, no. 2, pp. 343–350, 2007.
[37]
S. K. Motwani, S. Chopra, F. J. Ahmad, and R. K. Khar, “Validated spectrophotometric methods for the estimation of moxifloxacin in bulk and pharmaceutical formulations,” Spectrochimica Acta A, vol. 68, no. 2, pp. 250–256, 2007.
[38]
M. A. Sultan, “New, simple and validated kinetics spectrophotometric method for determination of moxifloxacine in its pharmaceutical formulations,” Arabian Journal of Chemistry, vol. 2, no. 2, pp. 79–85, 2009.
[39]
D. R. Chaple and K. P. Bhusari, “Spectrophotometric estimation of fluroquinolones as ion-pairs with bromocresol green in bulk and pharmaceutical dosage form,” Asian Journal of Chemistry, vol. 22, no. 4, pp. 2593–2598, 2010.
[40]
L. M. Abdellaziz and M. M. Hosny, “Development and validation of spectrophotometric, atomic absorption and kinetic methods for determination of moxifloxacin hydrochloride,” Analytical Chemistry Insights, vol. 6, no. 1, pp. 67–78, 2011.
[41]
G. H. Ragab and A. S. Amin, “Atomic absorption spectroscopic, conductometric and colorimetric methods for determination of fluoroquinolone antibiotics using ammonium reineckate ion-pair complex formation,” Spectrochimica Acta A, vol. 60, no. 4, pp. 973–978, 2004.
[42]
C. S. P. Sastry, K. R. Rao, and D. S. Prasad, “Extractive spectrophotometric determination of some fluoroquinolone derivatives in pure and dosage forms,” Talanta, vol. 42, no. 3, pp. 311–316, 1995.
[43]
S. Mostafa, M. El-Sadek, and E. A. Alla, “Spectrophotometric determination of ciprofloxacin, enrofloxacin and pefloxacin through charge transfer complex formation,” Journal of Pharmaceutical and Biomedical Analysis, vol. 27, no. 1-2, pp. 133–142, 2002.
[44]
S. Mostafa, M. El-Sadek, and E. A. Alla, “Spectrophotometric determination of enrofloxacin and pefloxacin through ion-pair complex formation,” Journal of Pharmaceutical and Biomedical Analysis, vol. 28, no. 1, pp. 173–180, 2002.
[45]
M. Rizk, F. Belal, F. Ibrahim, S. M. Ahmed, and N. M. El-Enany, “A simple kinetic spectrophotometric method for the determination of certain 4-quinolones in drug formulations,” Scientia Pharmaceutica, vol. 68, no. 1, pp. 173–188, 2000.
[46]
Z. A. El Sherif, “Spectrophotometric determination of enrofloxacin through the formation of a binary complex with iron III, ion-pair and charge-transfer complexation in pure and dosage forms,” Analytical Letters, vol. 32, no. 1, pp. 65–78, 1999.
[47]
C. S. P. Sastry, K. R. Rao, J. S. V. M. Lingeswara, and D. S. Prasad, “Two simple spectrophotometric methods for the assay of enrofloxacin in pharmaceutical dosage formulations,” Eastern Pharmacist, vol. 38, no. 1, pp. 143–144, 1995.
[48]
H. T. S. Britton, Hydrogen Ions, Chapman & Hall, New York, NY, USA, 4th edition, 1952.
[49]
P. Job, Spectrochemical Methods of Analysis, Wiley Interscience, New York, NY, USA, 1971.
[50]
J. H. Yoe and A. L. Jones, “Determination of tungsten,” Industrial and Engineering Chemistry, Analytical Edition, vol. 16, p. 111, 1944.
[51]
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology, Q2(R1), Complementary Guideline on Methodology dated 06 November 1996, ICH, London, UK, 2005.
[52]
J. N. Miller and J. C. Miller, Statistics and Chemometrics For Analytical Chemistry, Chapman & Hall/CRC, London, UK, 5th edition, 2005.
